Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

108.31 +0.05 (+0.05%)

Streaming Delayed Price Updated: 10:45 AM EST, Jan 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

99 100 Next >

Merck & Co Unusual Options Activity ↗

October 22, 2025

Via Benzinga

Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults

October 21, 2025

From Merck & Co., Inc.

Via Business Wire

What's Going On With Summit Therapeutics Stock On Monday? ↗

October 20, 2025

Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025.

Via Benzinga

2 Beaten-Down Stocks to Buy and Hold for the Next Decade ↗

October 20, 2025

That's plenty of time for these drugmakers to move past their challenges.

Via The Motley Fool

Market Minute: Dow Soars, Apple Hits Record High as 20-Day Government Shutdown Fuels Gold Rally

October 20, 2025

The U.S. financial markets opened the week with a robust performance on October 20, 2025, as the Dow Jones Industrial Average (DJIA) extended its gains, and tech giant Apple Inc. (NASDAQ: AAPL) reached...

Via MarketMinute

KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)

October 20, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia

October 20, 2025

From Merck & Co., Inc.

Via Business Wire

Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts

October 19, 2025

The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial

October 19, 2025

From Daiichi Sankyo

Via Business Wire

KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer

October 18, 2025

From Merck & Co., Inc.

Via Business Wire

Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients ↗

October 18, 2025

Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with bladder cancer.

Via Investor's Business Daily

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

October 18, 2025

From Merck & Co., Inc.

Via Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen

October 18, 2025

From Merck & Co., Inc.

Via Business Wire

Healthcare’s AI Revolution: Generative Intelligence Delivers Real Returns as Agentic Systems Drive Measurable Outcomes

October 17, 2025

The healthcare industry is experiencing a profound transformation, propelled by the accelerating adoption of artificial intelligence. While AI's potential has long been discussed, recent advancements...

Via TokenRing AI

Topics Artificial Intelligence Economy

Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program ↗

October 17, 2025

The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.

Via Stocktwits

UK Finance Minister Seeks More Pharma Investment In Exchange For Higher Drug Prices: Report ↗

October 16, 2025

UK finance minister Rachel Reeves told reporters that the country needs to be an attractive place for pharma, including in terms of pricing.

Via Benzinga

2 Dow Jones Stocks with Exciting Potential and 1 We Brush Off

October 16, 2025

The Dow Jones (^DJI) is home to corporate giants, but size alone doesn’t guarantee success. A few of these companies are struggling with weak fundamentals, paradigm shifts, or poor execution.

Via StockStory

Topics Artificial Intelligence Stocks

Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients ↗

October 16, 2025

Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer with a consistent safety profile.

Via Benzinga

Merck & Co. Inc. (NYSE:MRK) Demonstrates Dividend Strength and Sustainability ↗

October 16, 2025

Discover Merck (MRK), a top dividend stock with a sustainable 3.70% yield, strong profitability, and a solid financial health rating for reliable long-term income.

Via Chartmill

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer

October 16, 2025

From Merck & Co., Inc.

Via Business Wire

Dow Jones Stumbles with Fractional Dip, Signaling Cautious Market Sentiment Amidst Global Headwinds

October 15, 2025

New York, NY – October 15, 2025 – The Dow Jones Industrial Average (DJIA) experienced a fractional dip today, reflecting a palpable sense of caution pervading market sentiment. While other major...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials ↗

October 15, 2025

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 studies with stable weight outcomes.

Via Benzinga

Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection

October 15, 2025

From Merck & Co., Inc.

Via Business Wire

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential ↗

October 14, 2025

Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion.

Via Benzinga

Can $10,000 in Merck Stock Turn Into $50,000 by 2030? ↗

October 14, 2025

The pharmaceutical giant has seen brighter days.

Via The Motley Fool

Topics Intellectual Property

Absci's AI Revolution: A New Era for Drug Discovery or a Rocky Road Ahead?

October 13, 2025

Absci (NASDAQ: ABSI), a pioneer in AI-driven drug discovery, is making significant strides with its "Integrated Drug Creation™ Platform," promising to revolutionize how new medicines are brought to...

Via MarketMinute

Topics Artificial Intelligence

1 Cash-Producing Stock to Target This Week and 2 That Underwhelm

October 13, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk ↗

October 13, 2025

Absci's AI drug development platform is compelling, and its pipeline is promising...but can the company overcome execution hurdles to live up to analyst hype?

Via MarketBeat

Topics Artificial Intelligence

Dow Jones Soars on Trump's Tariff Remarks, Signaling Market Volatility Amidst Trade Policy Shifts

October 13, 2025

New York, NY – October 13, 2025 – The Dow Jones Industrial Average has experienced significant upward momentum in recent months, notably jumping by hundreds of points on multiple occasions in early...

Via MarketMinute

Topics Economy Government Stocks

Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday ↗

October 13, 2025

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.